drugset / Trial / NCT02171676

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

NCT02171676

Phase 1 Completed 40 enrolled Boehringer Ingelheim
RandomizedSingle-groupOpen-labelTreatment

Summary

Maximum tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic parameters, and efficacy of pulsatile administration of BIBW 2992 in combination with docetaxel (Taxotere®)

Timeline

Start
2005-05
Primary completion
2008-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Afatinib Small molecule
Background Docetaxel Small molecule

Indications